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Apoptosis, or programmed cell death, is a cellular pathway involved in normal cell turnover, developmental
tissue remodeling, embryonic development, cellular homeostasis maintenance and chemical-induced cell
death. Caspases are a family of intracellular proteases that play a key role in apoptosis. Aberrant activation
of caspases has been implicated in human diseases. In particular, numerous findings implicate Caspase-6
(Casp6) in neurodegenerative diseases, including Alzheimer disease (AD) and Huntington disease (HD), high-
lighting the need for a deeper understanding of Casp6 biology and its role in brain development. The use of
targeted caspase-deficient mice has been instrumental for studying the involvement of caspases in apop-
tosis. The goal of this study was to perform an in-depth neuroanatomical and behavioral characterization
of constitutive Casp6-deficient (Casp62/2) mice in order to understand the physiological function of
Casp6 in brain development, structure and function. We demonstrate that Casp62/2 neurons are protected
against excitotoxicity, nerve growth factor deprivation and myelin-induced axonal degeneration.
Furthermore, Casp6-deficient mice show an age-dependent increase in cortical and striatal volume. In add-
ition, these mice show a hypoactive phenotype and display learning deficits. The age-dependent behavioral
and region-specific neuroanatomical changes observed in the Casp62/2 mice suggest that Casp6 deficiency
has a more pronounced effect in brain regions that are involved in neurodegenerative diseases, such as the
striatum in HD and the cortex in AD.
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INTRODUCTION
Apoptosis, or programmed cell death, is a highly regulated
process involved in embryonic development, developmental
tissue remodeling and normal cell turnover (1,2). However,
when dysregulation occurs in apoptotic pathways, excessive
or insufficient cell death can lead to diseases such as
cancers, autoimmune syndromes and/or neurodegenerative
diseases (3,4). Caspases are a family of intracellular
cysteine-aspartic proteases that are not only essential for trig-
gering programmed cell death (5,6), but have also been shown
to play key roles in non-apoptotic pathways, such as differen-
tiation and proliferation of diverse cell types, axon guidance
and synaptic activity and plasticity (7–11).
Caspases are divided into long prodomain caspases
(caspases-2, -8, -9 and -10), which are initiators of apoptosis,
and short prodomain caspases (caspases-3, -6, -7 and -14),
which are generally termed the effectors of apoptosis (12).
However, some caspases, including caspase-3 (Casp3) and
caspase-6 (Casp6), appear to function as both initiators and
effectors. For example, active Casp6 is observed in preclinical
Alzheimer disease (AD) and Huntington disease (HD) brains
years prior to overt cell death and can activate caspases-2,
-3 and -8 (13–16). Similarly, activation of Casp3 has been
detected concomitantly with memory loss in a murine model
of AD and before obvious detection of cell death (17).
Casp3 has also been shown to activate Casp6 in certain experi-
mental paradigms (16).
Aberrant activation of caspases has been implicated in
several neurodegenerative diseases, such as AD, HD, various
ataxias and amyotrophic lateral sclerosis (13,18–22). Recent-
ly, Casp6 has also been implicated in ischemic brain injury
(23). In mouse models of AD, baseline Casp3 activity has
been shown to be elevated in hippocampal dendritic spines
(17). Interestingly, inhibiting caspase cleavage of b-amyloid
precursor protein (APP) at aa664, a described Casp6 cleavage
site, results in the rescue of AD-like behavioral and neuro-
pathological phenotypes (18,24–30). Furthermore, cleaved
APP binds to the death receptor 6 (DR6), which activates
Casp6, resulting in axonal degeneration in an AD mouse
model (31).
Casp6 cleavage of mutant huntingtin (mhtt) at amino acid
586 has also been shown to be a rate-limiting step in the patho-
genesis of HD (32,33). Mice carrying mhtt resistant to cleav-
age by Casp6 maintain normal neuronal function, do not
develop striatal neurodegeneration and are protected against
neurotoxicity (14,32,34–36). Recently, Casp6 activity levels
in the brain were also shown to be positively correlated with
CAG size and to be increased in persons carrying the mutation
but being asymptomatic (14).
Given the various findings implicating Casp6 in the progres-
sion of neurodegenerative diseases and the efforts underway to
identify Casp6 inhibitors as a therapeutic strategy for neuro-
logical diseases (37,38), understanding the normal role of
Casp6 in brain development and structure is crucial. There-
fore, the goal of this study was to perform an in-depth neuro-
pathological and behavioral characterization of mice lacking
in Casp6 (Casp62/2).
We demonstrate that Casp62/2 neurons are protected
against both nerve growth factor (NGF)-deprivation-induced
axonal degeneration and neurotoxic stimulus N-methyl-
D-aspartic acid (NMDA)-mediated excitotoxicity, thereby
strengthening the evidence for a crucial role for Casp6 in
this process. Similar to axons lacking p75 neurotrophin
receptor (p75NTR) (39), Casp62/2 axons were also
observed in the white matter tract of the corpus callosum,
which is uncommon in normal axons. These findings validate
the role of Casp6 in myelin-dependent axon degeneration in
the brain.
We show that Casp6-deficient mice show an age-dependent
increase in cortical and striatal volume. In addition, they show
a hypoactive phenotype and display a learning deficit. The
age-dependent behavioral and neuroanatomical changes
observed in the Casp62/2 mice suggest that Casp6 defi-
ciency has a more pronounced effect in brain regions including
the striatum and cortex that are initially affected in HD and
AD, respectively.
RESULTS
Casp62/2 brain and peripheral tissues show
no Casp6 expression
Exons 2–5 of the Casp6 gene encode the catalytic domain
of the Casp6 protein (40). These exons were removed to
generate Casp6 knockout (Casp62/2) mice that express a
truncated and inactive form of Casp6 (Supplementary Mater-
ial, Fig. S1A and B). Two PCR assays were designed for
genotyping: the wild-type (WT) assay amplifies the WT
allele from Casp6 WT and heterozygous (Casp6+/2) mice;
and the neo assay amplifies the knocked out allele from
Casp6+/2 and Casp62/2 mice. DNA extracted from
Casp62/2 mice shows PCR products generated with the
neo primers. In contrast, no PCR products are detected in
Casp62/2 DNA, using the WT primers (Supplementary
Material, Fig. S1C).
These mice were then examined by quantitative reverse
transcriptase PCR (qRT-PCR) and western analysis to
confirm the absence of Casp6 expression and Casp6 protein
in brain and peripheral tissues of Casp62/2 mice.
Quantitative RT-PCR shows no Casp6 mRNA expression in
Casp62/2 and reduced Casp6 mRNA expression in
Casp6+/2 brain tissue (Fig. 1A; ANOVA P ¼ 0.0001).
Western blotting using a Casp6 antibody demonstrates the
absence of the Casp6 protein in Casp62/2 cerebellum,
hippocampus, striatum, cortex, kidney, liver, spleen and
post-natal day 0 (P0) peripheral tissue (Fig. 1B). These
findings confirm that the Casp62/2 mice used in this study
constitutively lack Casp6.
Casp62/2 sympathetic neurons show protection against
axonal degeneration
Axonal degeneration is a crucial process for normal neurode-
velopment (41,42) and is disturbed in neurological disorders
(31,43,44). It has recently been established that axonal degen-
eration in both an AD mouse model and after growth factor
deprivation at axon terminals is mediated through the activa-
tion of Casp6 (31,39).
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Enhanced axonal degeneration may also explain the early
white matter loss that is seen in individuals with HD and
AD (45–47).
We investigated whether Casp62/2 sympathetic neurons
are protected from axonal degeneration after NGF withdrawal.
Sympathetic neurons were cultured in microfluidic chambers to
allow deprivation of NGF from the axon compartment. Al-
though axons of WT sympathetic neurons degenerate after
NGF deprivation (Fig. 2A and C; t-test P , 0.0001), NGF
withdrawal did not induce axonal degeneration in Casp62/2
sympathetic neurons (Fig. 2B and C; t-test P ¼ 0.24) (n ¼ 3
chambers/condition/genotype).
Medium spiny neurons from Casp61/2 and Casp62/2
mice show protection against NMDA-mediated
excitotoxicity in a Casp6-dose-dependent manner
Casp6 inhibitors and/or dominant-negative inhibition of Casp6
provide protection against excitotoxic stress (14,15). Therefore,
we hypothesized that medium spiny neurons (MSNs) derived
from Casp6-deficient mice might be protected from NMDAR-
mediated excitotoxicity. Casp62/2 MSNs demonstrate a sig-
nificant decrease in LDH levels (Fig. 3A; one-way ANOVA
P ¼ 0.01, post hoc Tukey WT versus Casp62/2 P , 0.05,
n ¼ 10 cultures), a significant increase in levels of ATP
(Fig. 3B; one-way ANOVA P ¼ 0.03, post hoc Tukey WT
versus Casp62/2 P , 0.05, n ¼ 10 cultures) and reduced
TUNEL-positive cells (Fig. 3C and Supplementary Material
S2; one-way ANOVA P ¼ 0.02, post hoc Tukey WT versus
Casp62/2 and WT versus Casp6+/2 P , 0.05, n ¼ 9–12
cultures) compared with WT MSNs post-NMDA treatment, in-
dicative of protection against NMDAR-mediated excitotoxicity
in Casp62/2 MSNs. Furthermore, post hoc linear trend test
reveals a dose-dependent effect, where the Casp6+/2 mice
also demonstrate partial rescue from NMDAR-mediated excito-
toxicity (post hoc test for linear trend, LDH: P ¼ 0.005; ATP:
P ¼ 0.01; TUNEL: P ¼ 0.02).
Casp6 is necessary for myelin-induced degeneration
of septal cholinergic axons in vivo
A recent study demonstrated that axon degeneration was an
ongoing process in the mature adult brain and implicated a
p75NTR-mediated pathway in this process. Immunostaining
of choline acetyltransferase (ChAT) allowed visualization of
cholinergic axons that projected from the forebrain to the
hippocampus by way of the supracallosal pathway, which is
immediately adjacent to the corpus callosum.
In WT mice, any axons of septal cholinergic neurons that
sprouted on to the myelinated corpus callosum degenerated,
whereas axons in p75NTR-null mice grew and survived on
this myelin tract (39). Since p75NTR-mediated axon degener-
ation requires Casp6 in vitro (39), we determined whether
genetic ablation of Casp6 inhibited axonal degeneration
in vivo.
Axon number and length were measured in 3- and
8-month-old mice. In Casp6+/2 mice, only a few short
ChAT-positive axons were observed on the white matter of
the corpus callosum (Fig. 4A), which is consistent with WT
littermate controls and previous WT data from the previous
study (39) (data not shown). Therefore, WT and Casp6+/2
data were combined as one control group. In contrast, in
brains of Casp62/2 mice, more ChAT-positive axons were
evident in the corpus callosum and many of these were very
long (Fig. 4A).
Quantification of these results verified that at 3 and
8 months of age, more ChAT-positive axons grew on the
corpus callosum in Casp62/2 versus control mice (Fig. 4B;
two-way ANOVA genotype: P ¼ 0.037, age: P , 0.0001,
interaction: P ¼ 0.76, n ¼ 3–4 controls, 3–4 Casp62/2),
and that the total length of these axons was significantly
increased (Fig. 4C; two-way ANOVA genotype: P ¼ 0.0015,
age: P , 0.0001, interaction: P ¼ 0.88, n ¼ 3–4 control,
3–4 Casp62/2). Even after normalizing for the increased
number of axons growing on the corpus callosum, axons in
Casp62/2 mice were significantly longer than those in
control mice at both ages (Fig. 4D; two-way ANOVA geno-
type: P ¼ 0.037, age: P ¼ 0.86, interaction: P ¼ 0.96, n ¼
3–4 control, 3–4 Casp62/2). Moreover, although many
ChAT-positive axons grew continuously over the white
matter in Casp62/2 brains, axons growing in the control
brains appeared to be degenerating (Fig. 4A).
Figure 1. No Casp6 expression is observed in Casp62/2 brain and peripheral
tissues. (A) Quantitative RT-PCR shows the absence of Casp6 mRNA expres-
sion in Casp62/2 brain tissue and reduced expression in Casp6+/2 brain
tissue when compared with WT (n ¼ 3–4/genotype). (B) Western blots
using Casp6 antibody show the absence of Casp6 protein in Casp62/2 cere-
bellum, hippocampus, striatum, cortex, kidney, liver, spleen and post-natal P0
peripheral tissue (n ¼ 3/genotype).
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Cortical and striatal volume is increased in older
Casp62/2 mice
Mendelian ratios and necropsy were examined prior to neuro-
anatomical studies to assess viability and gross peripheral
abnormalities in Casp6-deficient mice. Casp62/2 mice are
viable, breed normally and are born in appropriate Mendelian
ratios (Supplementary Material, Table S1). Additionally, nec-
ropsy performed on Casp62/2 mice revealed that the testis,
kidney, liver, heart, spleen, stomach, intestine, cecum and
colon of the Casp62/2 mice are normal compared with
WT mice (data not shown; n ¼ 1).
Deletions of specific caspases can result in robust brain mal-
formations associated with supernumerary cells, multiple cere-
bral indentations and ectopic cell masses in the cortex
(48–51). To determine whether Casp62/2 mice have any
brain malformations, brain and cerebellum weights were mea-
sured and more detailed structural and volumetric analyses
were examined through stereology in Casp62/2 mice at 3
and 8 months of age. Casp62/2 mice display normal brain
architecture at 3 months of age (Supplementary Material,
Fig. S2; one-way ANOVA cortical volume P ¼ 0.49, striatal
volume P ¼ 0.66, striatal neuronal counts P ¼ 0.23, brain
weight P ¼ 0.10, cerebellum weight P ¼ 0.50, n ¼ 20).
However, neuropathological analysis at 8 months reveals a
significant increase in cortical (Fig. 5A; one-way ANOVA
P ¼ 0.004, post hoc Tukey WT versus Casp62/2 and
Casp6+/2 versus Casp62/2 P , 0.05, n ¼ 6) and striatal
volume (Fig. 5A; one-way ANOVA P ¼ 0.02, post hoc
Tukey WT versus Casp62/2 P , 0.05, n ¼ 6) and in striatal
neuronal counts (Fig. 5A; one-way ANOVA P ¼ 0.03, post
hoc Tukey WT versus Casp62/2 P , 0.05, n ¼ 6).
Figure 2. Casp62/2 sympathetic neurons show protection against axonal degeneration. (A) WT axons from sympathetic neurons grown in microfluidic cham-
bers degenerate after NGF deprivation; in contrast, (B) NGF deprivation does not induce degeneration in axons from Casp62/2 mice. (C) Quantification of
axonal distance reveals a significant difference between control and NGF-deprived axons from WT mice (∗P , 0.0001) and no difference in the axons from
Casp62/2 mice regardless of treatment conditions (n ¼ 3 chambers/condition/genotype).
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Furthermore, post hoc test for linear trend reveals a dose-
dependent effect; the Casp6+/2 mice demonstrate an in-
crease in cortical and striatal volume and in striatal neuronal
counts compared with WT, but to a lesser extent than the
Casp62/2 mice (post hoc linear trend, cortex volume: P ¼
0.001; striatum volume: P ¼ 0.006; striatal neuronal counts:
P ¼ 0.01). However, no differences were observed in brain
(Fig. 5B; one-way ANOVA P ¼ 0.36, n ¼ 20) and cerebellum
weight (Fig. 5B; one-way ANOVA P ¼ 0.38, n ¼ 20) in
Casp62/2 mice compared with WT at 8 months of age.
Casp62/2 mice demonstrate a hypokinetic phenotype
and decreased novel object preference
Before conducting behavioral tests, we investigated body
weight in Casp62/2 mice. Longitudinal recording of body
weight shows no differences in body weight between
Casp62/2 and WT mice from 2 to 8 months of age
(females: RM ANOVA genotype: P ¼ 0.40, age: P ,
0.0001, interaction: P ¼ 0.95, n ¼ 7 WT, 9 Casp62/2;
males: RM ANOVA genotype: P ¼ 0.20, age: P , 0.0001,
interaction: P ¼ 0.42, n ¼ 4 WT, 10 Casp62/2).
In light of the neuroanatomical data, rotarod, total activity
and object recognition tasks were conducted to elucidate
whether Casp62/2 mice show behavioral deficits. Two inde-
pendent cohorts were tested for each behavioral task, and since
the results from the cohorts were not significantly different
for each test (ANOVA P . 0.05), the cohorts were pooled,
analyzed and presented below.
Casp6-deficient mice display motor coordination indistin-
guishable from WT mice during the accelerating rotarod
testing at all time-points assessed (Fig. 6A; factorial
ANOVA genotype: P ¼ 0.27, age: P , 0.0001, interaction:
P ¼ 0.86, n ¼ 19 WT, 21 Casp62/2). However,
Casp62/2 mice are hypoactive compared with WT mice
during the 30 min open-field trial that measures locomotor ac-
tivity (Fig. 6B; factorial ANOVA genotype: P ¼ 0.0017, age:
P ¼ 0.053, interaction: P ¼ 0.75, n ¼ 17 WT, 20 Casp62/2).
Furthermore, Casp62/2 mice display a deficit in the novel
object preference task when tested at 12 months (Fig. 6C; factor-
ial ANOVA genotype: P ¼ 0.37, trial: P , 0.0001, interaction:
P ¼ 0.0014, n ¼ 13 WT, 19 Casp62/2). In trial 2, WT animals
spend more time exploring the novel object that was not present
during trial 1 (Fig. 6C; post hoc Tukey P ¼ 0.00016), indicating
that they are able to distinguish the known object from the novel
one. However, Casp6-deficient mice did not spend significantly
more time exploring the novel object during trial 2 (Fig. 6C; post
hoc Tukey P ¼ 0.58), indicative of a learning deficit at this
time-point.
DISCUSSION
In this study, we provide evidence that Casp6 activity in vivo is
essential for axonal degeneration, as Casp62/2 neurons are
completely protected from NGF-deprivation-induced axonal
loss in vitro and do not undergo axonal degeneration on the
myelin in vivo. We further establish a role of Casp6 in NMDAR-
mediated excitotoxic cell death by demonstrating that
Casp62/2 and Casp6+/2 neurons are protected against
NMDA stimulation in a dose-dependent manner. In addition,
this study is the first to examine the neuroanatomical and
behavioral effects of ablating Casp6 in mice, which has identi-
fied age-dependent and region-specific changes in Casp62/2
mice.
Previous studies have demonstrated increased activity of
Casp6 in neurological diseases, including HD, AD and ische-
mia (13–15,23,31,32). Casp6 inhibitors and/or dominant-
negative inhibition of Casp6 have also suggested a role for
Casp6 in axonal degeneration (31,39).
Axonal degeneration is a key mechanism involved in devel-
opmental axonal pruning (41,42). However, it also occurs in
the mature nervous system as a consequence of neuronal
damage and contributes to neuronal loss in neurodegenerative
disorders (31,43,44). Patients with early HD display markedly
altered white matter in the corpus callosum, thalamus, sensori-
motor and prefrontal regions (45,46,52). Interestingly, white
matter pathways of the sensorimotor cortex and corpus callo-
sum are already reduced in pre-manifest HD subjects com-
pared with control subjects (46), indicating that axonal
degeneration is an early pathogenic event.
Magnetic resonance imaging analysis of the YAC128 full-
length mouse model of HD shows progressive white matter
loss that corresponds to alterations observed in human HD
(53). Axonal white matter is also reduced in AD patients at
the earliest stages of disease (47). Similarly, AD mouse
models show age-dependent axonal degeneration in the
Figure 3. MSNs from Casp6+/2 and Casp62/2 mice show protection against NMDA-mediated excitotoxicity in a Casp6-dose-dependent manner. Assess-
ment of susceptibility to excitotoxic stress demonstrates (A) a significant decrease in LDH levels (n ¼ 10 cultures/genotype), (B) a significant increase in levels
of ATP (n ¼ 10 cultures/genotype) and (C) a significant decrease in number of TUNEL-positive cells (n ¼ 9–12 cultures/genotype) in Casp62/2 MSNs com-
pared with WT post-NMDA stimulation. Post hoc linear trend tests reveal a dose-dependent effect; partial rescue from NMDA is observed in Casp6+/2 mice
(LDH: P ¼ 0.005; ATP: P ¼ 0.01; TUNEL: P ¼ 0.02).
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cortex, hippocampus, midbrain and hindbrain that likely con-
tributes to the motor and cognitive behavioral deficits
observed in these mice (54,55). In an AD mouse model,
axonal degeneration occurs through the activation of Casp6
(31,39,56), where the N-terminal fragment of cleaved APP
binds to DR6, activating Casp6 and resulting in axonal degen-
eration (31). The use of Casp6 inhibitors rescued the
APP-induced axonal degeneration, thereby implicating a crit-
ical role for Casp6 in this process. Casp6 activation also
leads to neurite degeneration in a process independent of
amyloid b-peptide (Ab) production from APP cleavage.
APP mutants that cannot generate Ab still induced neurite
beading and cell death, which are inhibited by Casp6 inhibi-
tors (56).
It has also been established that Casp6 is involved in focal
non-pathogenic axonal pruning along myelin tracks, such as in
the corpus callosum, in mice (39). Our findings show that
Casp62/2 sympathetic neurons are protected against
NGF-deprivation-mediated axonal degeneration in vitro and
Casp62/2 cholinergic neurons are protected from pruning
of their axons on the myelin-rich corpus callosum in vivo.
These data are consistent with Casp6 being necessary for
myelin-dependent axon degeneration in the intact adult brain.
Casp6 activity has been shown to be increased in the brains
of both early stage HD patients and in an HD mouse model
(14). In addition to axonal degeneration, we examined
whether Casp6 activity may play an important role in
NMDAR-induced excitotoxicity. Over-activation of glutamate
receptors is involved in the early stages of HD (57,58) and
several HD mouse models demonstrate enhanced susceptibil-
ity to glutamate and/or NMDAR-mediated excitotoxic stress
(14,57,59,60). The direct link between Casp6 activity and
enhanced NMDAR-mediated excitotoxic stress in HD mouse
models was demonstrated when MSNs expressing mhtt
showed Casp6 activation post-NMDA stimulation (14), and
protection against excitotoxic stress was observed with use
of Casp6 inhibitors and/or dominant negative inhibition of
Casp6 (14,15). Furthermore, mice expressing mhtt resistant
to cleavage by Casp6 do not show enhanced Casp6 activation
and demonstrate protection from excitotoxic stress (14,32) and
alterations in extrasynaptic NMDA receptors in vivo (35).
To further demonstrate that Casp6 has a crucial role in this
process, here we show that MSNs derived from Casp6+/2
and Casp62/2 mice show protection against NMDAR-
mediated excitotoxicity in a Casp6-dose-dependent manner.
The Casp6 dosage effect suggests that even partial inhibition
of Casp6 activity can be beneficial in reducing cell death
under excitotoxic conditions. This has important implications
for the potential therapeutic efficacy of Casp6 inhibitors in
neurological diseases where enhanced susceptibility to
NMDAR-mediated excitotoxicity has been shown. Our find-
ings provide further support that inhibition of Casp6 may
Figure 4. Casp6 is necessary for myelin-dependent axon degeneration in vivo.
(A) Sagittal sections through the corpus callosum and the adjacent supracallo-
sal pathway of adult control and Casp62/2 mice immunostained for ChAT.
Arrows denote ChAT-positive axons projecting into the corpus callosum, and
the boxed areas in the top panels denote regions of the corpus callosum that are
shown at higher magnification in the lower panels. Scale bar: 100 mm. Quan-
tification of the number (B), length (C) and average length (D) of ChAT-
positive axons projecting vertically into the corpus callosum anterior to the
splenium in control versus Casp62/2 mice. Error bars represent standard
error of the mean. ANOVA: ∗Geno P , 0.05, ∗∗Age P , 0.001; Post hoc
Tukey: ∗P , 0.05; n ¼ 3–4 each.
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represent a possible therapeutic target for neurodegenerative
diseases (37).
Given the importance of Casp6 in axonal degeneration and
excitotoxicity, both processes involved in HD and AD,
Casp62/2 mice were examined for neuroanatomical altera-
tions in regions affected in these neurodegenerative diseases.
Interestingly, we identified age-dependent and region-specific
neuroanatomical changes in the Casp62/2 mice. Neuroana-
tomical analysis at 8 months of age reveals a significant in-
crease in cortical and striatal volume and striatal neuronal
counts in Casp6-deficient mice compared with WT mice,
which were not observed at 3 months of age. Since increased
Casp6 activity is implicated in the pathogenesis of HD and
AD, where selective degeneration of neuroanatomical struc-
tures is progressive and becomes more severe and widespread
with advancing age (61–63), the age-dependent increase in
cortical and striatal volume observed in Casp62/2 mice is
congruent with evidence showing that Casp6 is required in
processes leading to neurodegeneration. The neuroanatomical
alterations observed in Casp6-deficient mice also provide
evidence that specific brain regions, such as the striatum and
cortex, are particularly sensitive to Casp6 activity in an
age-dependent manner.
Casp6 does not act alone and plays a crucial role in the
regulation of cell death pathway members. Although details
of apoptosis pathways are currently being elucidated, Casp9,
3 and 8 are shown to be key regulators and effectors of
Casp6 activity (23,64). Casp6 has recently been identified as
a downstream target of active Casp9, where inhibition of
Casp9 activity results in a lack of Casp6 activation and
protects against ischemic insult (23). Active Casp6 can then
initiate cell death pathways by activating Casp3 and 8
(64,65). Casp3 has been implicated in cell death; however,
during axonal pruning, Casp6 can activate Casp3 without in-
ducing cell death (31). Since Casp6 signals through other cas-
pases in the apoptosis and axonal pruning pathways, the
expression profiles of Casp6 and other caspases in the brain
may contribute to the region-specific neuroanatomical
changes observed in Casp62/2 mice. Casp6 expression is
observed predominantly in neurons, with higher expression
in MSNs in the striatum, compared with neurons in the
cortex, hippocampus and cerebellum (13–15,20,66,67)
(Allen Brain Atlas). Striatal MSNs also show high Casp7 ex-
pression compared with other brain regions, such as the cortex.
Interestingly, Casp7, in the absence of Casp3, can also func-
tionally compensate and ameliorate brain phenotypes seen in
Casp3-null mice (51). Unlike Casp6, Casp3 expression is
mostly expressed in glia (15), whereas Casp9 is detected in
cholinergic neurons and in pyramidal cells located in cortical
layer V, and Casp8 is ubiquitously expressed in different brain
regions. Therefore, a potential mechanism leading to initial
region-specific neurodegeneration in HD and AD could poten-
tially be caused by the regional and selective expression of
Casp6 and its interaction with other caspases involved in
regulating cell death.
Caspase activation can also be regulated by neurotrophic
factors (68). For example, deprivation of brain-derived neuro-
trophic factor (BDNF) has been shown to trigger cell death
pathways by activating caspases through increased p75NTR
signaling (69). The presence of BDNF provides protection
Figure 5. Cortical and striatal volume is increased in 8-month-old Casp62/2 mice. Neuropathological analysis at 8 months reveals (A) a significant increase in
cortical (n ¼ 6/genotype) and striatal (n ¼ 6/genotype) volume and in striatal neuronal counts (n ¼ 6/genotype). Post hoc linear trend test reveals a dose-
dependent effect; the Casp6+/2 mice demonstrate an increase in cortical and striatal volume and in striatal neuronal counts compared with WT, but to a
lesser extent than the Casp62/2 mice (post hoc linear trend, cortex volume: P ¼ 0.001; striatum volume: P ¼ 0.006; striatal neuronal counts: P ¼ 0.01).
However, no differences are observed in (B) brain (n ¼ 20/genotype) and cerebellum (n ¼ 20/genotype) weight in Casp62/2 mice compared with WT.
∗∗ANOVA P , 0.01; ∗ANOVA P , 0.05.
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against staurosporine-induced excitotoxic cell death in vitro by
activating the PI3K/Akt pathway through Trk receptor signal-
ing (70). BDNF has also been implicated in neuronal matur-
ation, axonal and dendritic branching and regeneration, and
in synaptic transmission and plasticity (71–73). Although
the pathways by which BDNF affects these processes are
still being elucidated, BDNF is known to regulate transcription
of Sprouty proteins, which modulate neuronal differentiation
and survival and axonal branching by inhibiting BDNF signal-
ing in a negative feedback loop (74,75). BDNF has also been
shown to play a key role in cognition and behavior by modu-
lating learning, anxiety and depression-like behaviors (76–78).
Interestingly, similar to Casp62/2 mice, Bdnf2/2 mice also
show structure-specific neuroanatomical alterations and
behavioral abnormalities. They display decreased dendritic
complexity and spine density in the cortex and hippocampus
and to an even greater extent in the striatum, where 90% of
the affected cells are GABAergic MSNs (79,80). Behavioral
changes associated with BDNF are also region-dependent,
and infusion of BDNF in the hippocampal dentate gyrus
reduces depression-like behaviors (81); however, infusion
into the nucleus accumbens increases depression (82) and
social aversion (83). These findings suggest that the diverse
responses to BDNF and/or Casp6 by different brain structures
may be mediated by region-intrinsic programs (79).
We further examined Casp62/2 mice using behavioral
tests to elucidate whether the neuroanatomical alterations
observed could result in cognitive changes. Casp62/2 mice
are hypoactive compared with WT mice during a 30 min open-
field test that measures locomotor activity. Striatal damage by
the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) has been shown to impair performance in an open-
field test, causing severe behavioral inactivity in distance
and speed of locomotion, peripheral activity and frequency
and duration of rearing (84). Interestingly, hypoactivity is
also observed in the full-length YAC HD mouse model,
where degeneration of the striatum is a key pathogenic
feature (61,62). These findings suggest that the striatum may
be involved in planning and executing pathways of movement.
We also show that by 12 months, Casp62/2 mice demon-
strate a deficit in the novel object recognition task. Excitotoxic
lesions of the perirhinal cortex have been shown to cause
deficits in object recognition tasks (85,86). Furthermore,
studies of neuronal activation in rats and monkeys suggest
that cortical neurons are involved in object recognition tasks
(87,88). Interestingly, AD mouse models also show
age-dependent cortical neuron pathology and deficits in
object recognition tasks (89–91), and intrastriatal quinolinic
acid injection in mice, which is an acute, in vivo HD model,
also causes object recognition impairment (92). Altogether,
these data suggest that the altered cortical and striatal
volume observed in the Casp6-deficient mice could comprom-
ise the normal function of these brain regions, and that these
changes could possibly translate into the learning impairment
and hypoactivity phenotype observed in the Casp62/2 mice.
Our data show that the behavioral and neuroanatomical
alterations observed in the Casp62/2 mice are age depend-
ent. This is consistent with data showing active Casp6 in
striatal and cortical neurons of WT mice starting at 9 and
12 months, respectively, with increased activation at 18
months of age. Microarray studies on the cortex and hypothal-
amus of BALB/c mice also show that Casp6 is significantly
up-regulated with age (93), and age-related activation
of Casp6 is also observed in human brain tissue (14).
Figure 6. Casp62/2 mice demonstrate normal motor coordination, a hypoki-
netic phenotype and decreased novel object preference. (A) Casp62/2 mice
display motor coordination indistinguishable from WT mice during rotarod
testing at all time-points assessed (n ¼ 19 WT, 21 Casp62/2).
(B) Casp62/2 mice are hypoactive compared with WT during a 30 min
open-field trial (ANOVA: ∗∗Geno P , 0.005, ∗Age, n ¼ 17 WT, 20
Casp62/2). (C) Casp62/2 mice demonstrate a deficit in a novel object
preference task at 12 months of age (∗Post hoc Tukey P , 0.001, n ¼ 13
WT, 19 Casp62/2).
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The normal age-dependent activation of Casp6 may explain
the neuropathological phenotype observed in the Casp62/2
mice, which only manifests with advanced age. Ablating
Casp6 while it is predominantly inactive may not cause any
brain alterations. However, its absence during a time when
Casp6 normally becomes activated could cause a decrease in
apoptosis and enlarged brain structures.
Our data highlight the importance of assessing whether
Casp6 inhibitors may offer protection against excitotoxic
stress and axonal degeneration in neurodegenerative diseases,
such as HD and AD. Although detrimental neuropathology is
only observed later in life, we have not yet ruled out whether
Casp6 deficiency during embryogenesis or development
may contribute to the behavioral abnormalities observed in
Casp6-deficient mice. Future studies with a conditional Casp6-
deficient mouse would allow examination of the morphologic-
al and behavioral impact of Casp6 deletion not only in specific
brain structures, but also at specific time-points.
MATERIALS AND METHODS
Generation of mutant Casp62/2 mice
The Casp62/2 mouse was created by Taconic Biosciences
by targeted gene disruption of Casp6 gene in embryonic
stem cells. Exons 2–5 of the Casp6 gene, which encode the
catalytic domain of the Casp6 protein, were disrupted in em-
bryonic stem cells by homologous recombination to generate
Casp62/2 mice (Supplementary Material, Fig. S1A and B).
The homologous recombination strategy was validated by
Southern analysis. Two PCR assays were designed for geno-
typing: the WT assay amplifies the WT allele from Casp6
WT and heterozygous (Casp6+/2) mice; and the mt allele
assay amplifies the knocked out allele from Casp6+/2 and
Casp62/2 mice. The following primers were used:
† WT assay forward: 5′-AGGGTGGGTTAGACCAGG
TT-3′;
† WT assay reverse: 5′-TCCAGCTTGTCTGTCTGGT
G-3′;
† mt assay forward: 5′-CCTGTGGGGTCAAAAGACTT
TCACAG-3′;
† mt assay reverse: 5′-GCAAGCTGCTAACAGCCAA
CACAAC-3′.
The PCR was performed in a 20 ml volume, using 1.5 ml of
genomic DNA in 10× PCR buffer, 50 mM MgCl2, 10 mM
dNTP, 2% formamide, 50% glycerol, Taq polymerase and
DH2O. A complex temperature profile was adopted to ensure
maximum specificity in the early rounds of amplification.
An initial DNA denaturation for 3 min at 948C was followed
by 35 cycles at 948C for 30 s, 608C for 1 min, 728C for
1 min and finally a 7 min extension at 728C.
Breeding and housing
The Casp6 knockout mouse, originally generated on the
C57Bl/6 (B6) strain, was backcrossed for five generations to
the FVB/NJ (FVB) strain. All the experiments, with the
exception of the necropsy and the Mendelian ratios, which
were performed and the data recorded on both the B6 and
FVB strains, were conducted on the incipient congenic mice
on the FVB strain and according to the protocols approved
by the University of British Columbia Committee on Animal
Care (protocol A07-0106). The mice were housed in groups
of maximum five mice per cage as previously described (61).
mRNA analysis and qRT-PCR
RNA was extracted from Casp62/2 and WT mice whole
brain using the RNeasy Mini Kit (Qiagen, 74104). cDNA
was prepared using 250 ng of total RNA and the
Superscript-III First-Strand Synthesis Kit with oligo-dT
priming (Invitrogen, 11752-050). SYBR Green PCR Master
Mix (Applied Biosystems, 4309155) in the ABI7500 instru-
ment was used to perform the quantitative real-time PCR
with the absolute quantification standard curve method. The
following primers were used:
† mouse Casp6 forward: 5′-CAACGCAGACAGAGACA
ACCT-3′;
† mouse Casp6 reverse: 5′-TCGACACCTCGTGAATTT
TGAG-3′;
† mouse actin forward: 5′-ACGGCCAGGTCATCACTA
TTG-3′;
† mouse actin reverse: 5′-CAAGAAGGAAGGCTGGA
AAAGA-3′.
Protein analysis and western blotting
Protein was extracted as previously described (94) from brain
and peripheral tissues from Casp62/2 and WT mice and its
concentration measured by Bio-Rad DC Protein Assay. Four
to 12% Bis–Tris polyacrylamide gels from Invitrogen were
used to load 70 mg of protein for brain and peripheral
tissues in LDS sample buffer (Invitrogen, NP0008) after it
was denatured by heating it to 708C. Proteins were transferred
to an Immobilon-PVDF-FL membrane and probed with a
Casp6 antibody (Cell Signaling 9762, 1:500) and calnexin
antibody (Sigma C4731, 1:5000).
Necropsy
Kidney, liver, heart, spleen, stomach, intestine, cecum, colon
and testis tissues were collected from one B6 Casp62/2
mouse and one FVB Casp62/2 mouse, and stored in 10%
formalin. A #15 scalpel blade was used to cut the tissues
into 3–4 mm sections; they were placed into cassettes and
then set in a paraffin block and cut into 1 mm slices using a
microtome. They were mounted into slides and a hematoxylin
and eosin stain was applied in order to perform a macroscopic
examination of the different tissues cell structure.
NMDAR-mediated excitotoxicity
Cultures (9–12 individual cultures) of primary MSNs were
prepared from P0–P1 Casp62/2 and WT pups in a
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procedure described previously (32,58). Cultures were main-
tained in vitro for 9–10 days, after which they were exposed
to balanced salt solution (BSS) or 500 mm NMDA (Sigma)
in BSS for 10 min. Twenty-four hours after NMDA, cultures
were fixed and assessed for apoptotic cell death using
TUNEL staining (Roche) and morphological criteria (small,
condensed nuclei) by propidium iodide (Sigma) counterstain-
ing. For each experiment, all treatments were done blind, in
triplicate, and a minimum of 1000 cells counted.
LDH and ATP were assessed in separate cultures. Twenty-
four hours after stress, 50 ml of culture media were used for
LDH quantification, according to the manufacturer’s instruc-
tions (Roche, Cytotoxicity Detection Kit). For ATP assess-
ment, CellTiter-Glo Luminescent Cell Viability Assay from
Promega was used. Cells were lysed on an orbital rotator at
room temperature for 10 min. One hundred microliters of
cell lysis was removed to a black 96-well plate and lumines-
cence recorded with PolarStar Omega plate reader. In
order to obtain the LDH and ATP data, the raw value of
each well was normalized to BSS-treated cells/neurons on
the same plate.
NGF-induced axonal degeneration in microfluidic
chambers
Sympathetic neurons were isolated as previously described
(95) from P0–P1 WT and Casp-6 2/2 mice. Briefly,
PDMS (Sylgard 183, Dow Corning) replica-molded microflui-
dic chambers (96) were placed onto glass cover slips coated
with poly-D-lysine (50 mg/ml) and laminin (1 mg/ml). Disso-
ciated sympathetic cervical ganglion neurons (approximately
20 000 cells) were plated into the somatic compartment and
maintained in NGF-containing (50 ng/ml) media for 5–6
days. For localized NGF deprivation, the axon compartment
was rinsed three times with medium lacking NGF and then
maintained in 70 ml of NGF-free media containing an
anti-NGF-neutralizing antibody. One hundred liters of
NGF-containing media remained in the somatic compartment
to create a 30 ml volume differential between the two compart-
ments. The volume differential was carefully maintained
during local deprivation to prevent any medium exchange
between soma and axon compartments.
Fixed neurons were then probed with tubulin (Sigma T9026,
1:400), using standard immunofluorescence techniques. Nuclei
were stained with Hoechst 33258 (Molecular Probes). Images
were acquired by an ORCA-ER digital B/W CCD camera
(Hamamatsu) mounted on a DMIRE2 inverted fluorescence
microscope (Leica), using the Metamorph version 7.6 software
(Molecular Devices). Adobe Photoshop was used to scale
down and crop images to prepare the final figures.
The Metamorph version 7.6 software was used to measure
horizontal axon distance (mm) from the left outer edge of
the central channels (where the axons exit the channels and
enter the axon compartment) to the farthest point of axon
growth inside the axon compartment. Unbiased measurements
were obtained by measuring axon distance at every sixth
channel within the same chamber both before and after treat-
ment. To calculate fold change, the mean post-treatment axon
distance was divided by the mean pre-treatment axon distance.
Fold change in axon distance was calculated for three
chambers per condition. Graph values represent the average
fold change in axon distance + standard error of the mean
(SEM) (n ¼ 3).
Stereology
Quantitative analysis was done blind to genotype. Mice were
terminally anesthetized by intra-peritoneal injection of 2.5%
avertin and perfused with 3% paraformaldehyde/0.15% glutar-
aldehyde in phosphate-buffered saline (PBS). Mouse brains
were post-fixed in the same solution for 24 h at 48C and
then cryoprotected in 30% sucrose prior to coronal sectioning
on a cryostat (MICROM HM 500 M, MICROM, Heiderberg,
Germany) at 25 mm. Every eighth section throughout the stri-
atum from the bregma (1.34 to 20.94 mm) was collected and
stained with an antibody reactive to NeuN (Chemicon), a
marker of neuronal nuclei (93), as described previously (61).
The area of the striatum was traced with the Stereoinvesti-
gator 10.0 software (Microbrightfield, Williston, VT, USA).
For neuronal counts, the physical fractionator probe was
used with a grid size of 500 × 500 and counting frame of
25 × 25 and the nucleator probe was used for the measure-
ment of neuronal size. A minimum of 200–300 cells per
animal were counted and analyzed. For striatal volume, the
Cavalieri principle was employed where the total striatal
area was multiplied by section thickness (25 mm) and section-
al sampling interval (8) as previously described (97,98) (n ¼
20/genotype at 3 months, n ¼ 6/genotype at 8 months). The
cortex was delineated using the corpus callosum as the
ventral boundary in the same sections used for striatal ana-
lyses. Cortical volume was determined according to the Cava-
lieri principle as previously described (97,98) (n ¼ 20/
genotype at 3 months, n ¼ 6/genotype at 8 months).
For analysis of cholinergic axons in the CNS, adult mice
were anesthetized, intracardially perfused with ice-cold 0.9%
NaCl and fixed with 4% paraformaldehyde (Electron Micros-
copy Sciences). Brains were post-fixed for 6 h in 4% parafor-
maldehyde at 48C and cryoprotected in 30% (w/v) sucrose in
PBS, and sagittal serial 40 mm sections were collected in cryo-
protectants. For diaminobenzidine staining, we analyzed every
third section from 0–480 mm away from the midline, using
standard immunohistochemical procedures (39). Briefly, sec-
tions were rinsed three times for 10 min each in TBS, incu-
bated in 0.6% H2O2 for 15 min and blocked in Tris buffer
containing 5% donkey serum and 0.25% Triton X-100. Sec-
tions were incubated overnight at 48C in primary antibody,
anti-ChAT (1:200, Chemicon), diluted in blocking solution.
Sections were rinsed three times for 10 min each in TBS
and incubated with a biotinylated donkey-anti-goat secondary
antibody for 2 h at room temperature. Sections were then
rinsed and processed with avidin–biotin complex (Vectastain
Elite, Vector Laboratories) and 3′,3′-diaminobenzidine
(Vector). Sections were rinsed, mounted onto gelatin-coated
glass slides, dried overnight, dehydrated in an alcohol gradi-
ent, washed in xylene and cover-slipped using Permount
(Fisher). For immunofluorescence staining, random sections
from 0–480 mm away from the midline were rinsed three
times for 10 min each in PBS, blocked in PBS containing
10% donkey serum, 2% horse serum and 0.25% Triton
X-100, incubated overnight at 48C in blocking solution plus
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primary antibody, rinsed three times for 10 min each in PBS,
incubated with secondary antibody for 2 h at room tempera-
ture, rinsed and mounted using Fluoromount (Sigma-Aldrich)
(n ¼ 3–4/genotype at 3 and 8 months).
Body weight
Mice were weighed at 2, 4, 6 and 8 months of age using a digital
scale and weight recorded. Female: WT (n ¼ 7) and Casp62/2
(n ¼ 9). Male: WT (n ¼ 4) and Casp62/2 (n ¼ 10).
Behavior
Behavioral analysis of Casp62/2 and WT mice was done
blind to genotype.
Rotarod
Motor coordination and learning were examined using an
accelerating rotarod (UGO Basile, Comerio, Italy). For train-
ing, naı̈ve 2-month-old mice were given three trials of 2 min
on a fixed speed (18 r.p.m.) task per day for three days (nine
trials total). The inter-trial interval (ITI) was 2 h. Mice
falling from the rod were returned, to a maximum of 10
falls/trial. The time to first fall and the total number of falls
per trial were recorded. For accelerating rotarod assessment,
mice were tested at 2, 4 and 8 months of age on a rod accel-
erating from 5 to 40 r.p.m. for 300 s. Latency to fall from the
rod was recorded. Three trials in 1 day were averaged to give
mean performance for each mouse at each age (n ¼ 19 WT, 21
Casp62/2).
Open-field activity monitoring
Mice (n ¼ 17 WT, 20 Casp62/2) were assessed using an
open-field activity monitor (Med Associates, Inc., St Albans,
VT, USA) during the dark cycle at 2, 6 and 8 months of
age. Mice were placed in the testing chamber for 30 min,
total activity was recorded and measurements were calculated
using the accompanying software (Med Associates). The
testing chambers were wiped clean with water between mice.
Novel-object recognition
Mice (n ¼ 13 WT, 19 Casp62/2) were placed at the lower
left corner of a 50 × 50 cm2 open grey acrylic box with a
20 × 20 cm center in a room brightly lit by fluorescent
ceiling lights. Open-field activity was recorded for 10 min
by a ceiling-mounted video camera. Distance traveled, mean
velocity, entries into the 20 × 20 cm2 center and time spent
in the center of the center point of the mouse were scored
using the Ethovision 7.0 XT software (Noldus).
After open-field exploration, which allows acclimation to
the testing arena, mice were returned to their home cage for
a 5 min ITI. Two different novel objects of sufficient height
and weight to prevent mice from moving or climbing on
them were placed at the upper two corners of the box, far
enough from the sides so as to not impede movement
around the outer edge (8 cm). Mice were re-introduced
into the box at the lower left corner and recorded for 5 min,
during which the number of investigations of the objects
was scored as frequency and duration of the nose point of
the mouse entering the zone immediately around the object,
using the Ethovision XT software. Mice were then removed
from the box for a 5 min interval, and the object at the top
right corner of the box was replaced by a different unfamiliar
object in the same location. Mice were re-introduced into the
box and recorded for 5 min and the number and duration of
investigations of the objects were scored. For novel-object
preference testing, the percentage of the investigations to the
target object (the unfamiliar one) was computed. For
novel-object location, the experiment was repeated on the sub-
sequent day, but rather than replacing the object with an un-
familiar one, the object at the top right corner of the box
was moved to the lower right corner of the box. The percent-
age of the investigations to the target object (the one in the
new location) was computed.
Statistics
Statistical analysis (i.e. P-values, means and SEMs) was per-
formed using Prism, version 4.0 (GraphPad Software). Differ-
ences between means were considered statistically significant
if P , 0.05.
Axon distance before and after NGF deprivation was mea-
sured and fold change was calculated by dividing the mean
post-treatment axon distance by the mean pre-treatment axon
distance. Fold change in axon distance was calculated for
three chambers per condition. Graph values represent the
average fold change in axon distance+SEM (n ¼ 3). An un-
paired Student’s t-test was used to determine whether there
was a statistically significant difference between treatment
conditions. The t-test was also used to analyze the number
and length of ChAT-positive axons in the corpus callosum.
Statistical analysis of the LDH, ATP and TUNEL data, as
well as of the stereology data, was performed using one-way
ANOVA. Significant genotype effects were followed up with
post hoc Tukey comparisons and post hoc linear trend tests.
Statistical analysis of the body weight was performed using
a repeated-measures ANOVA model. For rotarod data, a fac-
torial ANOVA was used to determine genotype, age and geno-
type–age interaction effects. Similarly, for the novel-object
recognition test, a factorial ANOVA was used to determine
genotype, trial and genotype–trial interaction effects. Signifi-
cant effects were followed by post hoc Tukey comparison test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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